AMPH Q2 2020 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$86M+8.6% YoY

Gross Profit

$33M38.7% margin

Operating Income

-$3M-3.4% margin

Net Income

-$192,000-0.2% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$19M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$600M

Total Liabilities

$158M

Stockholders' Equity

$398M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$79M	+8.6%
Gross Profit	$33M	$32M	+2.4%
Operating Income	-$3M	$973,000	-400.3%
Net Income	-$192,000	$48M	-100.4%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$5M100%

Geographic Segments

U

$82M100%

C

$295,0000%